Lung metastasis alone in nasopharyngeal carcinoma: A relatively favorable prognostic group

Hui, Edwin P.; Leung, Sing Fai; Au, Joseph Siu-Kie; Zee, Benny; Tung, Stewart Y.; Chua, Daniel T.T.; Sze, W.M.; Law, C.K.; Leung, TW; Chan, Anthony T.C.

doi:10.1002/cncr.20358

Cited by 175 publications

(127 citation statements)

References 21 publications

Supporting

Mentioning

116

Contrasting

Order By: Relevance

“…2,3 Ionizing radiation (IR) causes damage to cellular structures of irradiated cells, including DNA. IR induces DNA damage either by directly damaging the DNA or by indirectly generating reactive oxygen species, which ultimately alter the chemical structure of DNA, leading tumor cells to halting cellular proliferation and initiating a DNA damage response.…”

Section: Discussionmentioning

confidence: 99%

“…It has been reported that approximately 30% of patients presenting localized tumors develop recurrent disease, and 30-60% of patients with metastatic NPC die within 5 years of diagnosis. 2,3 The mechanisms that cause NPC radiotherapy resistance are elusive. 4 IKKα is a subunit of IκB kinase (IKK) complex that consists of two highly homologous kinase subunits (IKKα and IKKβ) and a nonenzymatic regulatory component, IKKγ/NEMO.…”

mentioning

confidence: 99%

See 1 more Smart Citation

IKKα-mediated biogenesis of miR-196a through interaction with Drosha regulates the sensitivity of cancer cells to radiotherapy

et al. 2016

View full text Add to dashboard Cite

Radioresistance is a major obstacle in successful clinical cancer radiotherapy, and the underlying mechanisms are not clear. Here we show that IKKα-mediated miR-196a biogenesis via interaction with Drosha regulates the sensitivity of nasopharyngeal carcinoma (NPC) cells to radiotherapy. Phosphorylation of IKKα at T23 site (p-IKKαT23) promotes the binding of IKKα to Drosha that accelerates the processing of miR-196a primary transcripts, leading to increased expressions of both precursor and mature miR-196a. Dephosphorylation of p-IKKαT23 downregulates miR-196a expression and promotes the resistance of NPC cells to radiation treatment. The miR-196a mimic suppresses while its inhibitor promotes the resistance of NPC to radiation treatment. Importantly, the expression of p-IKKαT23 is positively related to the expression of miR-196a in human NPC tissues, and expression of p-IKKαT23 and miR-196a is inversely correlated with NPC clinical radioresistance. Thus, our studies establish a novel mechanistic link between the inactivation of IKKαT23-Drosha-miR-196a pathway and NPC radioresistance, and de-inactivation of IKKαT23-Drosha-miR-196a pathway would be an efficient way to restore the sensitivity of radioresistant NPC to radiotherapy.

show abstract

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

IKKα-mediated biogenesis of miR-196a through interaction with Drosha regulates the sensitivity of cancer cells to radiotherapy

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Several previous studies suggested that a small proportion of patients with metastatic NPC were potentially curable by aggressive chemotherapy. 6,7,26 However, no specific indicator for this subgroup of patients was identified. In the current study, we found that 21.7% of patients with low pre-treatment plasma EBV DNA level (<median) and undetectable post-treatment plasma EBV DNA level were free of disease at 5-year follow-up, suggesting that plasma EBV DNA might be considered as an indicator for aggressive chemotherapy to achieve long-term survival.…”

Section: -21mentioning

confidence: 99%

“…For selected patients, survival rates exceeding 4 years have been reported. 6,7 It is therefore critical to define reliable prognostic factors to identify patients with good or poor prognosis. Currently, evaluation of prognosis for metastatic NPC patients treated with palliative chemotherapy mainly relies on clinical characteristics, including performance status and disease-free interval.…”

mentioning

confidence: 99%

Plasma Epstein-Barr virus DNA level strongly predicts survival in metastatic/recurrent nasopharyngeal carcinoma treated with palliative chemotherapy

An¹,

Wang²,

Ding³

et al. 2011

Cancer

138

115

View full text Add to dashboard Cite

BACKGROUND: Plasma Epstein-Barr virus (EBV) DNA is widely used in screening, monitoring, and prediction of relapse in nonmetastatic nasopharyngeal carcinoma (NPC). However, data regarding utility of plasma EBV DNA in metastatic NPC are rare. The current study was to test the prognostic implication of plasma EBV DNA level in metastatic/recurrent NPC patients treated with palliative chemotherapy. METHODS: Plasma EBV DNA level was measured at baseline and thereafter at the start of each treatment cycle in 127 histologically proven metastatic/recurrent NPC patients treated with palliative chemotherapy. Correlations of pre-treatment and post-treatment plasma EBV DNA levels to survival and response were analyzed. RESULTS: Patients with a low pre-treatment plasma EBV DNA level (

show abstract

“…CCRT that is based on cisplatin (CDDP)-containing regimes, is the current standard therapy for locally advanced NPC (9,10). Whilst this approach has improved the 3 year OS and disease-free survival (DFS) rates to ~80% and 70%, respectively (9)(10)(11)(12)(13)(14), patients remain at a high risk of developing distant metastases following treatment (15-19% for all patients) (15)(16)(17), and CCRT is insufficient for patients with extensive nodal disease or bulky tumors.…”

Section: Introductionmentioning

confidence: 99%

Evaluation of the efficacy and safety of a neoadjuvant gemcitabine and nedaplatin regimen followed by radiotherapy or concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma

2015

View full text Add to dashboard Cite

Abstract. The aim of the present study was to evaluate the efficacy and safety of a neoadjuvant gemcitabine and nedaplatin chemotherapy regimen, followed by concurrent chemoradiotherapy or radiotherapy alone, in locoregionally advanced nasopharyngeal carcinoma (NPC). Eighty-six patients with stage III, IVA or IVB NPC, who received neoadjuvant chemotherapy [gemcitabine, 1,000 mg/m 2 on day 1 (d1) and d5; nedaplatin, 25 mg/m 2 on d 1-3] every 3 weeks for at least two cycles, followed by intensity-modulated radiotherapy every 3 weeks, with or without concurrent nedaplatin (25 mg/m 2 , d1-3) between September 2010 and December 2013, were retrospectively analyzed. By comparing pretreatment and post-treatment MRI images, it was shown that seven patients achieved a complete response (8.5%), while 66 achieved a partial response (80.5%), following completion of neoadjuvant chemotherapy (combined response rate, 89.0%). Grade 3-4 toxicities following neoadjuvant chemotherapy included neutropenia (29.1%), leukopenia (11.6%), liver dysfunction (9.3%), thrombocytopenia (9.3%) and nausea/vomiting (8.1%). The median follow-up was 18 months (range, 5-44 months). The 2-year relapse-free survival, distant metastasis-free survival, progression-free survival and overall survival rates were 96.6, 85.4, 83.3 and 96.1%, respectively. Compared with alternative neoadjuvant chemotherapy regimens in combination with radiotherapy or concurrent chemoradiotherapy, the present gemcitabine and nedaplatin did not provide additional survival benefit and led to a higher frequency of liver dysfunction. Therefore, neoadjuvant gemcitabine and nedaplatin should be used with caution in locoregionally advanced NPC.

show abstract

Lung metastasis alone in nasopharyngeal carcinoma: A relatively favorable prognostic group

Cited by 175 publications

References 21 publications

IKKα-mediated biogenesis of miR-196a through interaction with Drosha regulates the sensitivity of cancer cells to radiotherapy

IKKα-mediated biogenesis of miR-196a through interaction with Drosha regulates the sensitivity of cancer cells to radiotherapy

Plasma Epstein-Barr virus DNA level strongly predicts survival in metastatic/recurrent nasopharyngeal carcinoma treated with palliative chemotherapy

Evaluation of the efficacy and safety of a neoadjuvant gemcitabine and nedaplatin regimen followed by radiotherapy or concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma

Contact Info

Product

Resources

About